Healtcare Antibiotics and Corticosteroids Market | Page 2

The use of antibiotics with the combination of corticosteroids has proven effective in the treatment
of human respiratory syncytial virus (hRSV) infection, Cepacia syndrome, S. Aureus arthritis,
pneumonia, Zika Virus, and Ebola. According to the data published in Journal of Tropical Diseases
and Public Health, in 2016, around 6.3 million children died in 2013, wherein 51.8% died due to
infectious diseases and largest was accounted due to pneumonia for around 935,000 deaths.
However, around 3.4 million children are infected with the human Respiratory syncytial virus
(RSV) which is associated to acute lower respiratory infections (ALRI). Supportive government
activities in the favor of antibiotics and corticosteroids production is helping to boost the antibiotic
and corticosteroids market. For instance, introduction of Antibiotics Incentives Now (GAIN) act
which has the provisions to facilitate the development of therapy against antigen resistant pathogens
is expected to propel the approval for antibiotics.
However, some of the restraints which are likely to hamper the growth of antibiotics and
corticosteroids market include the adverse effect on high intake or misuse of both antibiotics and
corticosteroids, use in animals which are later consumed by humans, and regulations and policies on
use of antibiotics and corticosteroids.
Rising cases of infectious diseases and established healthcare sector is fuelling to the growth of
antibiotics and corticosteroids market in North America
Regional segmentation of antibiotics and corticosteroids market by Coherent Market Insights
comprises of North America, Latin America, Europe, Asia Pacific, the Middle East and Africa.
North America hold the major share in the antibiotics and corticosteroids market due to the high
prevalence rate of respiratory syncytial virus (RSV) infection and the need of antibiotic and
corticosteroids treatment of such diseases. For instance, the data given by Centers for Disease
Control and Prevention (CDC), around 2.1 million children are diagnosed with RSV and 14, 000
adult population die due to this disease annually. Latin America also hold the large share in the
antibiotics and corticosteroids market followed by Asia Pacific due to the progress in
pharmaceutical industry.
Industry players are involved in the regional expansion and collaborations with other
companies to hold the larger share in the antibiotics and corticosteroids market
Key industry players operating the global antibiotics and corticosteroids market include Novartis,
Pfizer, GlaxoSmithKline (GSK), Abbott Laboratories, Sanofi, Johnson & Johnson, Merck,
Sumitomo, AstraZeneca, Cipla, and Astellas Pharma. The generic drug manufacturers are
dominating in the antibiotics and corticosteroid market due to the presence of key drugs that are
helping to generate the revenue with availability of few patent products. Adoption of various
strategies such as regional expansion, novel product development, collaborations, and partnerships
by the industry players to hold the major share in the antibiotics and corticosteroids market. For
instance, Pfizer made an agreement with AstraZeneca in 2016, which has helped to acquire the
commercialization and development right to the Pfizer’s business mostly outside the U.S.
For More Information @
https://www.coherentmarketinsights.com/ongoing-insight/antibiotics-and-corticosteroids-
market-781
Rise in population with pneumonia is contributing to the growth of this disease segment in
antibiotics and corticosteroids market